|Net Assets||7.23 Mil|
|Morningstar Return||Below Average|
- Last NAV update 12/6/2013 4:00 PM ET
|The investment seeks long-term capital growth. The fund invests at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or "market capitalization"). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. Under adverse market conditions, it may also make temporary investments in investment grade debt securities. Such investment strategies could result in the Portfolio not achieving its investment objective. The fund is non-diversified.|
- Year to date performance as of 12/6/2013 12:00 AM ET
|Fund Manager||Mark Oelschlager|
|Minimum Initial Purchase||250.00|
|Minimum IRA Investment||NA|
- * Annualized returns
- Performance as of 12/6/2013 12:00 AM ET
|Net Assets||7.23 Mil||693.18 Mil|
|Avg Market Cap||25.38 Bil||24.01 Bil|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.